Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Resolving Spacetime Singularities within Asymptotic Safety.

Bosma L, Knorr B, Saueressig F.

Phys Rev Lett. 2019 Sep 6;123(10):101301. doi: 10.1103/PhysRevLett.123.101301.

PMID:
31573312
2.

A robust optimization technique for analysis of multi-tracer experiments.

Gharasoo M, Wietzke LM, Knorr B, Bakkour R, Elsner M, Stumpp C.

J Contam Hydrol. 2019 Jul;224:103481. doi: 10.1016/j.jconhyd.2019.04.004. Epub 2019 Apr 11.

PMID:
31005265
3.

Towards Reconstructing the Quantum Effective Action of Gravity.

Knorr B, Saueressig F.

Phys Rev Lett. 2018 Oct 19;121(16):161304. doi: 10.1103/PhysRevLett.121.161304.

PMID:
30387657
4.

Analytical transport modelling of metabolites formed in dual-porosity media.

Knorr B, Maloszewski P, Stumpp C.

Environ Sci Pollut Res Int. 2017 Feb;24(5):4447-4456. doi: 10.1007/s11356-016-8115-x. Epub 2016 Dec 9.

PMID:
27943139
5.

Gravitational Two-Loop Counterterm Is Asymptotically Safe.

Gies H, Knorr B, Lippoldt S, Saueressig F.

Phys Rev Lett. 2016 May 27;116(21):211302. doi: 10.1103/PhysRevLett.116.211302. Epub 2016 May 26.

PMID:
27284643
6.

Quantifying the impact of immobile water regions on the fate of nitroaromatic compounds in dual-porosity media.

Knorr B, Maloszewski P, Stumpp C.

J Contam Hydrol. 2016 Aug;191:44-53. doi: 10.1016/j.jconhyd.2016.05.002. Epub 2016 May 16.

PMID:
27236346
7.

Predictors of asthma following severe respiratory syncytial virus (RSV) bronchiolitis in early childhood.

Lu S, Hartert TV, Everard ML, Giezek H, Nelsen L, Mehta A, Patel H, Knorr B, Reiss TF.

Pediatr Pulmonol. 2016 Dec;51(12):1382-1392. doi: 10.1002/ppul.23461. Epub 2016 May 6.

8.

Demonstration of single crystal growth via solid-solid transformation of a glass.

Savytskii D, Knorr B, Dierolf V, Jain H.

Sci Rep. 2016 Mar 18;6:23324. doi: 10.1038/srep23324.

9.

Influence of colloids on the attenuation and transport of phosphorus in alluvial gravel aquifer and vadose zone media.

Pang L, Lafogler M, Knorr B, McGill E, Saunders D, Baumann T, Abraham P, Close M.

Sci Total Environ. 2016 Apr 15;550:60-68. doi: 10.1016/j.scitotenv.2016.01.075. Epub 2016 Jan 22.

PMID:
26803685
10.

The asthma disease activity score: a discriminating, responsive measure predicts future asthma attacks.

Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen L, Gates DF Jr, Kuo WL, Smugar SS, Reiss TF, Barnes N, Fuhlbrigge A, Milgrom H, Schatz M, Knorr B.

J Allergy Clin Immunol. 2012 Nov;130(5):1071-1077.e10. doi: 10.1016/j.jaci.2012.07.057. Epub 2012 Oct 1.

PMID:
23036744
11.

"To wheeze or not to wheeze": that is not the question--the sequel.

Bisgaard H, Swern AS, Knorr B.

J Allergy Clin Immunol. 2012 Aug;130(2):531-2. doi: 10.1016/j.jaci.2011.10.047. Epub 2012 Feb 24. No abstract available.

PMID:
22365706
12.

Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.

Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:73-86. doi: 10.2147/COPD.S29444. Epub 2012 Feb 3.

13.

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.

Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:57-71. doi: 10.2147/COPD.S27320. Epub 2012 Feb 3.

14.

Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.

Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Banerjee S, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:43-55. doi: 10.2147/COPD.S27319. Epub 2012 Feb 3. Erratum in: Int J Chron Obstruct Pulmon Dis. 2012;7:765.

15.

Airway obstruction lability helps distinguish levels of disease activity in asthma.

Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen LM, Smugar SS, Noonan G, Reiss TF, Knorr BA.

Respir Med. 2012 Apr;106(4):500-7. doi: 10.1016/j.rmed.2011.12.013. Epub 2012 Jan 31.

16.

Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast.

Wasfi YS, Kemp JP, Villarán C, Massaad R, Xin W, Smugar SS, Knorr BA, Philip G.

Allergy Asthma Proc. 2011 Nov-Dec;32(6):453-9. doi: 10.2500/aap.2011.32.3482.

PMID:
22221440
17.

The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma.

Wasfi YS, Villarán C, de Tilleghem Cle B, Smugar SS, Hanley WD, Reiss TF, Knorr BA.

Respir Med. 2012 Jan;106(1):34-46. doi: 10.1016/j.rmed.2011.08.019. Epub 2011 Sep 25.

18.

Intermittent or daily montelukast versus placebo for episodic asthma in children.

Valovirta E, Boza ML, Robertson CF, Verbruggen N, Smugar SS, Nelsen LM, Knorr BA, Reiss TF, Philip G, Gurner DM.

Ann Allergy Asthma Immunol. 2011 Jun;106(6):518-26. doi: 10.1016/j.anai.2011.01.017. Epub 2011 Mar 4.

PMID:
21624752
19.

MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease.

Bernstein JA, Liu N, Knorr BA, Smugar SS, Hanley WD, Reiss TF, Greenberg S.

Respir Med. 2011 Mar;105(3):392-401. doi: 10.1016/j.rmed.2010.09.021. Epub 2010 Nov 13.

20.

Bioequivalence of the 4-mg Oral Granules and Chewable Tablet Formulations of Montelukast.

Knorr B, Hartford A, Li XS, Yang AY, Noonan G, Migoya E.

Arch Drug Inf. 2010 Jun;3(2):37-43.

21.

A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma.

Camargo CA Jr, Gurner DM, Smithline HA, Chapela R, Fabbri LM, Green SA, Malice MP, Legrand C, Dass SB, Knorr BA, Reiss TF.

J Allergy Clin Immunol. 2010 Feb;125(2):374-80. doi: 10.1016/j.jaci.2009.11.015.

PMID:
20159247
22.

Analysis of behavior-related adverse experiences in clinical trials of montelukast.

Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, Knorr B.

J Allergy Clin Immunol. 2009 Oct;124(4):699-706.e8. doi: 10.1016/j.jaci.2009.08.011. Erratum in: J Allergy Clin Immunol. 2010 May;125(5):1019.

PMID:
19815116
23.

Reports of suicidality in clinical trials of montelukast.

Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, Knorr B.

J Allergy Clin Immunol. 2009 Oct;124(4):691-6.e6. doi: 10.1016/j.jaci.2009.08.010.

PMID:
19815114
24.

Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions.

Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, Knorr B, Noonan G.

Pediatr Pulmonol. 2009 Jun;44(6):568-79. doi: 10.1002/ppul.21018. Review.

PMID:
19449366
25.

Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma.

Lu S, Liu N, Dass SB, Reiss TF, Knorr BA.

Respir Med. 2009 Mar;103(3):342-7. doi: 10.1016/j.rmed.2008.10.024. Epub 2009 Jan 8.

26.

Predicting an asthma exacerbation in children 2 to 5 years of age.

Swern AS, Tozzi CA, Knorr B, Bisgaard H.

Ann Allergy Asthma Immunol. 2008 Dec;101(6):626-30. doi: 10.1016/S1081-1206(10)60226-8.

PMID:
19119707
27.

Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children.

Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, Marchal JL, Dass SB, Reiss TF, Knorr BA.

Am J Respir Crit Care Med. 2008 Oct 15;178(8):854-60. doi: 10.1164/rccm.200706-910OC. Epub 2008 Jun 26.

PMID:
18583576
28.

Prevalence of hepatitis B virus infection among women at reproductive age at a German university hospital.

Knorr B, Maul H, Schnitzler P.

J Clin Virol. 2008 Aug;42(4):422-4. doi: 10.1016/j.jcv.2008.03.009. Epub 2008 Apr 29.

PMID:
18448387
29.

Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis.

Kearns GL, Lu S, Maganti L, Li XS, Migoya E, Ahmed T, Knorr B, Reiss TF.

J Clin Pharmacol. 2008 Apr;48(4):502-11. doi: 10.1177/0091270008314251. Epub 2008 Feb 22.

PMID:
18296556
30.
31.

Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children.

Pedersen S, Agertoft L, Williams-Herman D, Kuznetsova O, Reiss TF, Knorr B, Dass SB, Wolthers OD.

Pediatr Pulmonol. 2007 Sep;42(9):838-43.

PMID:
17659605
32.

A haemophagocytic lymphohistiocytosis (HLH)-like picture following breastmilk transmitted cytomegalovirus infection in a preterm infant.

Knorr B, Kessler U, Pöschl J, Fickenscher H, Linderkamp O.

Scand J Infect Dis. 2007;39(2):173-6.

PMID:
17366039
33.

Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study.

Becker AB, Kuznetsova O, Vermeulen J, Soto-Quiros ME, Young B, Reiss TF, Dass SB, Knorr BA; Pediatric Montelukast Linear Growth Study Group.

Ann Allergy Asthma Immunol. 2006 Jun;96(6):800-7.

PMID:
16802767
34.

Pharmacokinetics and safety of montelukast in children aged 3 to 6 months.

Knorr B, Maganti L, Ramakrishnan R, Tozzi CA, Migoya E, Kearns G.

J Clin Pharmacol. 2006 Jun;46(6):620-7.

PMID:
16707408
35.

Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis.

Patel P, Philip G, Yang W, Call R, Horak F, LaForce C, Gilles L, Garrett GC, Dass SB, Knorr BA, Reiss TF.

Ann Allergy Asthma Immunol. 2005 Dec;95(6):551-7.

PMID:
16400895
36.

Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma.

van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF.

Curr Med Res Opin. 2005 Jun;21(6):971-9.

PMID:
15969897
37.

A population pharmacokinetic model for montelukast disposition in adults and children.

Ramakrishnan R, Migoya E, Knorr B.

Pharm Res. 2005 Apr;22(4):532-40. Epub 2005 Apr 7.

PMID:
15846460
38.

The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma.

Davies GM, Dasbach EJ, Santanello NC, Knorr BA, Bratton DL.

Clin Ther. 2004 Nov;26(11):1895-904.

PMID:
15639701
39.

Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%.

Becker A, Swern A, Tozzi CA, Yu Q, Reiss T, Knorr B.

Curr Med Res Opin. 2004 Oct;20(10):1651-9.

PMID:
15462699
40.

Heart rate variability during sleep and the early development of posttraumatic stress disorder.

Mellman TA, Knorr BR, Pigeon WR, Leiter JC, Akay M.

Biol Psychiatry. 2004 May 1;55(9):953-6.

PMID:
15110740
41.

Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old.

Migoya E, Kearns GL, Hartford A, Zhao J, van Adelsberg J, Tozzi CA, Knorr B, Deutsch P.

J Clin Pharmacol. 2004 May;44(5):487-94.

PMID:
15102869
42.

Response to montelukast among subgroups of children aged 2 to 14 years with asthma.

Meyer KA, Arduino JM, Santanello NC, Knorr BA, Bisgaard H.

J Allergy Clin Immunol. 2003 Apr;111(4):757-62.

PMID:
12704354
43.

Safety of chewable tablets for children.

Michele TM, Knorr B, Vadas EB, Reiss TF.

J Asthma. 2002 Aug;39(5):391-403. Review.

PMID:
12214893
44.

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.

Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL.

Pediatrics. 2001 Sep;108(3):E48.

PMID:
11533366
45.

Use of oral montelukast in the treatment of asthma.

Noonan GP, Williams B, Angner R, Lu S, Knorr B, Reiss TF.

Compr Ther. 2001 Summer;27(2):148-55. Review.

PMID:
11430263
46.

Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older.

Williams B, Noonan G, Reiss TF, Knorr B, Guerra J, White R, Matz J.

Clin Exp Allergy. 2001 Jun;31(6):845-54.

PMID:
11422148
47.

Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults.

Knorr B, Nguyen HH, Kearns GL, Villaran C, Boza ML, Reiss TF, Rogers JD, Zhang J, Larson P, Spielberg S.

J Clin Pharmacol. 2001 Jun;41(6):612-9.

PMID:
11402629
48.

Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years.

Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, Shingo S, Reiss TF.

Clin Exp Allergy. 2001 Jan;31(1):77-87.

PMID:
11167954
49.

Validation of a pediatric asthma caregiver diary.

Santanello NC, Demuro-Mercon C, Davies G, Ostrom N, Noonan M, Rooklin A, Knorr B.

J Allergy Clin Immunol. 2000 Nov;106(5):861-6.

PMID:
11080707
50.

Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections.

Knorr B, Holland S, Rogers JD, Nguyen HH, Reiss TF.

J Allergy Clin Immunol. 2000 Sep;106(3 Suppl):S171-8. Review.

PMID:
10984399

Supplemental Content

Support Center